SEC Form 4 · accession 0001127602-16-044666
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Staab II
Officer — Senior Vice President and CFO
Period of report
Mar 1, 2016
Accepted (ET)
Mar 3, 2016 · 9:43 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 1, 2016 | F | 465 | $2.13 | D | 144,628 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2012.